

PRODUCT INFORMATION

# Anti-Dupilumab antibody

Anti-Dupilumab is a chimeric rabbit/mouse anti-idiotypic antibody targeting the therapeutic antibody Dupilumab. It has rabbit variable domains and mouse constant domains and mainly binds to free Dupilumab in samples.

Article number	M9263
Product group	Recombinant Antibody
Technique	ELISA

AntiBodyChain  
[www.antibodychain.com](http://www.antibodychain.com)  
[order.handling@antibodychain.com](mailto:order.handling@antibodychain.com)  
+31(0) 43 2010 660  
Wim Duisenbergplantsoen 31  
6221SE  
Maastricht

## Technical information sheet

Plesmanlaan 125  
1066 CX Amsterdam  
P.O. Box 9190  
1006 AD Amsterdam  
The Netherlands

### Anti-Dupilumab antibody

**M9263**


*For research use only*

#### Application

Anti-Dupilumab is a chimeric rabbit/mouse anti-idiotypic antibody that specifically targets the human therapeutic antibody Dupilumab. The antibody consists of rabbit variable domains and mouse constant domains. The antibody binds mainly to free Dupilumab in samples.

Dupilumab is a human IgG4/kappa antibody directed to both the interleukin-4 (IL-4) and IL-13 receptors, blocking the receptor signalling pathways<sup>(1)</sup>.

Anti-Dupilumab antibody has been evaluated in ELISA<sup>(2-5)</sup>, other techniques need to be validated by the user. It is recommended to test the antibody by titration of the product in the used technique using appropriate negative/positive controls.



**Figure 1:** Titration of Dupilumab to create a pharmacokinetic (PK) curve in bridging ELISA. Anti-Dupilumab antibody was used as capture (0.5 µg/ml) and detection antibody (0.250 µg/ml) in sandwich assay format.<sup>(5)</sup> DPL= Dupilumab

## References

1. European Medicines Agency (EMA). Dupixent (dupilumab). <https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent>. 2024.
2. Bosma AL, Gerbens LAA, El Khattabi H, Loeff FC, Duckworth M, Woolf RT et al. The clinical relevance of dupilumab serum concentration in patients with atopic dermatitis: a two-center prospective cohort study. *Journal of Dermatological Treatment* 2023; 34. PMID:37098906.
3. Spekhorst LS, De Graaf M, Loeff F, Zuithoff NPA, Bakker D, Boesjes CM et al. Association of Serum Dupilumab Levels at 16 Weeks with Treatment Response and Adverse Effects in Patients with Atopic Dermatitis: A Prospective Clinical Cohort Study from the BioDay Registry. In: *JAMA Dermatology*. American Medical Association, 2022, pp 1409–1413 PMID:36322072.
4. Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. *Allergy: European Journal of Allergy and Clinical Immunology* 2022; 77: 3398–3407. PMID:35837880.
5. Großerichter-Wagener C, Kos D, van Leeuwen A, Dijk L, Jeremiasse J, Loeff FC et al. Biased anti-idiotypic response in rabbits leads to high-affinity monoclonal antibodies to biologics. *MAbs* 2020; 12. PMID:32887534.